Adherence and persistence to a regimen of basal insulin in a pre-filled pen compared to vial/syringe in insulin-nave patients with type 2 diabetes

Current Medical Research and Opinion

Volumn 27, Issue 9, 2011, Pages 1709-1717

  Buysman, Erin ^a   Conner, Christopher ^b   Aagren, Mark ^b   Bouchard, Jonathan ^b   Liu, Fang ^a  

^a OPTUM   (United States)

^b NOVO NORDISK INC   (United States)

Author keywords

Adherence; Claims analysis; Diabetes; Insulin initiation; Pen device; Persistence

Indexed keywords

INSULIN; INSULIN DETEMIR; ISOPHANE INSULIN;

ADULT; ARTICLE; COMORBIDITY; DRUG COST; DRUG DELIVERY SYSTEM; DRUG DOSAGE FORM COMPARISON; FEMALE; HEALTH CARE COST; HUMAN; INSULIN PEN; INSULIN TREATMENT; MAJOR CLINICAL STUDY; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; PATIENT COMPLIANCE; QUAN CHARLSON COMORBIDITY SCORE; RETROSPECTIVE STUDY; SCORING SYSTEM; SYRINGE; TREATMENT OUTCOME; VIAL;

ADULT; AGED; ALGORITHMS; DIABETES MELLITUS, TYPE 2; DISPOSABLE EQUIPMENT; FEMALE; HUMANS; HYPOGLYCEMIC AGENTS; INSULIN, ISOPHANE; INSULIN, LONG-ACTING; MALE; MEDICATION ADHERENCE; MIDDLE AGED; PHARMACEUTICAL PREPARATIONS; RETROSPECTIVE STUDIES; SYRINGES;

EID: 80051715214     PISSN: 03007995     EISSN: 14734877     Source Type: Journal    
DOI: 10.1185/03007995.2011.598500     Document Type: Article

References (32)

1. Miser WF. The management of type 2 diabetes mellitus FOCUS on quality. Prim Care 2007;34:1-38 (Pubitemid 46671604)
2. National Diabetes Statistics, 2011. Available at: http://www.diabetes. org/diabetes-basics/diabetes-statistics/[Last accessed 18 March 2011]
3. Ginsberg HN, MacCallum PR. The obesity, metabolic syndrome, and type 2 diabetes mellitus pandemic: Part I. Increased cardiovascular disease risk and the importance of atherogenic dyslipidemia in persons with the metabolic syndrome and type 2 diabetes mellitus. J Cardiometab Syndr 2009;4:113-119
4. Narayan KM, Boyle JP, Thompson TJ, et al. Lifetime risk for diabetes mellitus in the United States. JAMA 2003;290:1884-1890 (Pubitemid 37430605)
5. The Diabetes Control and Complications Trial Research Group. The effect of intensive treatment of diabetes on the development and progression of longterm complications in insulin-dependent diabetes mellitus. N Engl J Med 1993;329:977-986
6. UK Prospective Diabetes Study (UKPDS) Group. Intensive blood glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 1998;352:837-53
7. UK Prospective Diabetes Study (UKPDS) Group. Effect of intensive bloodglucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). Lancet 1998;352:854-65
8. Brown JB, Pedula KL, Bakst AW. The progressive cost of complications in type 2 diabetes mellitus. Arch Intern Med 1999;159:1873-1880 (Pubitemid 29424707)
9. Menzin J, Langley-Hawthorne C, Friedman M, et al. Potential short-term economic benefits of improved glycemic control: a managed care perspective. Diabetes Care 2001;24:51-5 (Pubitemid 32104219)
10. Wagner EH, Sandhu N, Newton KM, et al. Effect of improved glycemic control on health care costs and utilization. JAMA 2001;285:182-189 (Pubitemid 32048520)
11. Nathan DM, Buse JB, Davidson MB, et al. Medical management of hyperglycemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy: a consensus statement of the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care 2009;32:193-203
12. Centers for Disease Control and Prevention (CDC), National Center for Health Statistics, Division of Health Interview Statistics, data from the National Health Interview Survey. Available at: http://www.cdc.gov/diabetes/ statistics/meduse/fig2.htm [Last accessed 8 February 2011]
13. Pladevall M, Williams LK, Potts LA, et al. Clinical outcomes and adherence to medications measured by claims data in patients with diabetes. Diabetes Care 2004;27:2800-2805 (Pubitemid 39565040)
14. Lee WC, Balu S, Cobden D, et al. Prevalence and economic consequences of medication adherence in diabetes: a systematic literature review. Manag Care Interface 2006;19:31-41 (Pubitemid 44148014)
15. Rhee MK, Slocum W, Ziemer DC, et al. Patient adherence improves glycemic control. Diabetes Educ 2005;31:240-250 (Pubitemid 40529013)
16. Ho PM, Rumsfeld JS, Masoudi FA, et al. Effect of medication nonadherence on hospitalization and mortality among patients with diabetes mellitus. Arch Intern Med 2006;166:1836-1841 (Pubitemid 44455165)
17. Mollema ED, Snoek FJ, Pouwer F, et al. Diabetes Fear of Injecting and Self-Testing Questionnaire: a psychometric evaluation. Diabetes Care 2000;23:765-769 (Pubitemid 30414190)
18. Mollema ED, Snoek FJ, Ader HJ, et al. Insulin-treated diabetes patients with fear of self-injecting or fear of self-testing: psychological comorbidity and general well-being. J Psychosom Res 2001;51:665-72 (Pubitemid 34007445)
19. Martinez L, Consoli SM, Monnier L, et al. Studying the Hurdles of Insulin Prescription (SHIP): development, scoring, and initial validation of a new selfadministered questionnaire. Health Qual Life Outcomes 2007;5:53-63
20. Peyrot M, Rubin RR, Kruger DF, et al. Correlates of insulin injection omission. Diabetes Care 2010;33:240-245
21. Korytkowski M, Bell D, Jacobsen C, Suwannasari R; FlexPen Study Team. A multicenter, randomized, open-label, comparative, two-period crossover trial of preference, efficacy, and safety profiles of a prefilled, disposable pen and conventional vial/syringe for insulin injection in patients with type 1 or 2 diabetes mellitus. Clin Ther 2003;25:2836-2848 (Pubitemid 37510593)
22. Korytkowski M, Niskanen L, Asakura T. FlexPen: addressing issues of confidence and convenience in insulin delivery. Clin Ther 2005;27:S89-S100 (Pubitemid 43866930)
23. Kadiri A, Chraibi A, Marouan F, et al. Comparison of NovoPen 3 and syringes/vials in the acceptance of insulin therapy in NIDDM patients with secondary failure to oral hypoglycaemic agents. Diabetes Res Clin Pract 1998;41:15-23 (Pubitemid 28394280)
24. Summers KH, Szeinbach SL, Lenox SM. Preference for insulin delivery systems among current insulin users and nonusers. Clin Ther 2004; 26:1498-505 (Pubitemid 39572159)
25. Baser O, Bouchard J, DeLuzio T, et al. Assessment of adherence and healthcare costs of insulin device (FlexPen) versus conventional vial/syringe. Adv Ther 2010;27:94-104
26. Quan H, Sundararajan V, Halfon P, et al. Coding algorithms for defining comorbidities in ICD-9-CM and ICD-10 administrative data. Med Care 2005;43:1130-1139 (Pubitemid 41587600)
27. Sokol MC, McGuigan KA, Verbrugge RR, et al. Impact of medication adherence on hospitalization risk and healthcare cost. Med Care 2005;43: 521-530 (Pubitemid 40847288)
28. White TJ, Vanderplas A, Chang E, et al. The costs of non-adherence to oral antihyperglycemic medication in individuals with diabetes mellitus and concomitant diabetes mellitus and cardiovascular disease in a managed care environment. Dis Manage Heath Outcomes 2004;12:181-188 (Pubitemid 38845095)
29. Lau DT, Nau DP. Oral antihyerglycemic medication nonadherence and subsequent hospitalization among individuals with type 2 diabetes. Diabetes Care 2004;27:2149-2153 (Pubitemid 39167177)
30. Asche CV, Shane-McWhorter L, Raparla S. Health economics and compliance of vials/syringes versus pen devices: a review of the evidence. Diabetes Technol Ther 2010;12(Suppl 1):S101-108
31. Bonafede MM, Kalsekar A, Pawaskar M, et al. A retrospective database analysis of insulin use patterns in insulin-na?̈ve patients with type 2 diabetes initiating basal insulin or mixtures. Patient Prefer Adherence 2010;4:147-156
32. Vanelli M, Pedan A, Liu N, et al. The role of patient inexperience in medication discontinuation: a retrospective analysis of medication nonpersistence in seven chronic illnesses. Clin Ther 2009;31:2628-2652